DUBLIN, Sept. 3, 2020 /PRNewswire/ -- The "Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" clinical trials has been added to ResearchAndMarkets.com's offering.

The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology. The relevance that it has shown for the welfare of the society and pharmaceutical industry has led to the development of a transdisciplinary environment that is however conducive to innovation with a mission to abolish the limitations in the pharmaceutical industry through excellence in microbiome research, awareness and outreach. Over the years now, gut microbiome is estimated to implicate success for the various immunotherapies.

Microbiome's role in immunology practices is to transform world-class treatment into the medicine of today and tomorrow. It is highly recognizable that the healthcare issues that mankind is facing today is now bigger than any one solution. The treatment of certain diseases requires multiple options for the treatment and ultimately prevention. Therefore, the amalgamation of two different treatment paradigms i.e. microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time. The ways in which microbiome is understood and manipulated to serve the immunological aspects has given great interest to all the researchers.

The essential and usual concept of immunology depicts targeting the immune system of the body to provoke an immune response with huge impact but then the unsuccessful implication of immunology therapies driven treatments led to an exploration of several other basic concepts that could play an important role in boosting the immune system when combined. Looking forward, the microbiome community in the gut represented beneficial patterns with respect to further research. The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.

All over the world, the amalgamation of the two has been well accepted and appreciated by the patients, physicians and the clinicians. Investigation of all the working sides of microbiome and how it plays an important role in boosting the manipulated immune cells have recently started in large numbers as the technology available in the medical field allows to capture it accurately. To facilitate the microbiome and immunology community in order to extract the best and trending opportunities that are stemmed into the microbiome research, the experts from both the relevant disciplines are analyzing it through clinical researches and surveys. Further, the area is getting supported by 86 different clinical trials getting conducted in different countries.

The Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025 report summarizes the view of the wider opportunities that are associated microbiome community for the advancement of the scientific information regarding immunology. The science that is related to microbiome has high interdisciplinary and various opportunities that somehow have remained hidden in the medical world. It is believed that the opportunities and all the desirable tangible benefits microbiome is capable of delivering when combined with immunology is large and needs coordinated and constructive approach. The call to the two different sectors i.e. microbiology and immunology is estimated to unlock the potential and promising benefits of microbiome. The approach leading to the extraction of advantages if properly embedded in the microbiome and immunology research, the future benefits will be huge

Report Highlights:

Key Topics Covered:

1. Overview of Microbiome 1.1 Introduction to Microbiome 1.2 History & Evolution of Microbiome

2. Role of Microbiome in Human Body

3. Microbiome: Various Forms 3.1 Gut Microbiome 3.2 Lung Microbiome 3.3 Skin Microbiome 3.4 Microbiome in Other Parts of the Body

4. Mechanism of Microbiome Activity 4.1 Nature of Immune Response 4.1.1 Immunosuppressive Activity 4.1.2 Immunostimulatory Activity 4.2 Messengers Involves in Microbiome Mechanism 4.2.1 MAMPs/PAMPs 4.2.2 Microbial Metabolites As Messengers 4.2.3 Host Cytokines As Messengers 4.2.4 Immune Cells As Messengers

5. Technological Requirement for Microbiota 5.1 Technologies Used 5.1.1 iChip 5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME) 5.1.3 Gut-on-a-Chip System 5.1.4 Colonic Stem Cell Construction 5.2 Harnessing & Engineering the Microbiome 5.2.1 Additive Approaches 5.2.2 Subtractive Approaches

6. Need for Microbiome Immunology

7. Therapeutic Applications of Microbiome Immunology 7.1 Microbiome Therapy 7.2 Precision Medicine 7.3 Drug discovery 7.4 Biomarkers & Therapy Optimization

8. Human Microbiota in Infectious Diseases 8.1 Infection with Clostridium Difficile 8.2 Infection with Helicobacter Pylori 8.3 Bacterial Vaginosis 8.4 Infection with HIV

9. The Human Microbiota & Liver Diseases 9.1 Non-Alcoholic Fatty Liver Disease (NAFLD) 9.2 Alcoholic Liver Diseases (ALD) 9.3 Liver Fibrosis & Cirrhosis

10. The Human Microbiota & Metabolic Disorders 10.1 Obesity 10.2 Type 2 Diabetes

11. The Human Microbiota & Other Diseases 11.1 Microbiota & Allergic Diseases 11.2 Microbiota & Psychiatric Diseases

12. Microbiome in Immuno Oncology 12.1 Role of Microbiome in Immuno Oncology 12.2 Microbiome Mechanism in Oncogenesis & Tumor Suppression

13. Microbiome Application by Cancer Types 13.1 Gastric Cancer 13.2 Colorectal Cancer 13.3 Esophageal Cancer 13.4 Hepatocellular Carcinoma 13.5 Melanoma 13.6 Solid Tumors

14. Industrial Approaches of Microbiome Therapy in Oncology 14.1 Bacterial Approaches 14.1.1 Fecal Microbiota Transplantation (FMT) 14.1.2 Synthetic Bacteria 14.1.3 Microbial Culture 14.2 Microbiome as Vaccine 14.3 Microbiome as Small Molecules 14.4 Microbiome Therapy using Phage Virus

15. Global Human Microbiome Market Analysis 15.1 Overview 15.2 Human Microbiome Market Segmentation 15.2.1 Regional Segmentation 15.2.2 Disease Based Segmentation 15.2.3 Segmentation by Application

16. Clinical Pipeline of Microbiome Based Therapy 16.1 Microbiome Modulators in Clinical Trial 16.2 Cancer Related Clinical Trials 16.2.1 Preclinical & Discovery Phase 16.2.2 Active Clinical Trials 16.3 Clinical Trial Related To FMT 16.3.1 Clinical Trial for Recurrent C. difficile 16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD) 16.3.3 Other FMT Related Clinical Trials

17. Global Microbiome Modulators Clinical Pipeline By Company, Indication & Phase 17.1 Research 17.2 Preclinical 17.3 Clinical 17.4 Phase-I 17.5 Phase-I/II 17.6 Phase-II 17.7 Phase-II/III 17.8 Phase-III

18. Marketed Microbiome Modulators Clinical Insight 18.1 Sodium Oligomannurarate - Shanghai Green Valley Pharmaceutical 18.2 Miya-BM

19. Global Microbiome Immunology Therapeutics Market Growth Drivers

20. Microbiome Technology - Investments, Acquisitions & Collaborations by Leading Microbiome Companies

21. Blockades in the Microbiome Immunology Market 21.1 Stable Engraftment 21.2 Development of Clinically Relevant Sensors 21.3 Robustness and Evolutionary Stability of Genetic Circuits 21.4 Regulation, Safety and Biocontainment

22. Global Microbiome Immunology Market Future Panorama

23. Competitive Landscape 23.1 4D Pharma 23.2 AbbVie 23.3 AstraZeneca plc 23.4 Biocodex 23.5 Bristol Mayer Squibb 23.6 Corebiome/Diversigen 23.7 Elogi Bioscience 23.8 Enterome 23.9 Ferring Pharmaceuticals 23.10 Finch Therapeutics 23.11 Maat Pharma 23.12 Merck 23.13 Microbiome Therapeutics 23.14 Novartis 23.15 OpenBiome 23.16 Pfizer 23.17 Rebiotix 23.18 Second Genome 23.19 Seres Therapeutics 23.20 Symberix 23.21 Takeda Pharmaceuticals 23.22 Vedanta Bioscience

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/u5kzzz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original post:
Worldwide Human Microbiome Immunology Therapeutics Industry to 2025 - The US Dominates the Global Market Landscape - PRNewswire